PERINDOPRIL ERBUMINE/INDAPAMIDE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

PERINDOPRIL ERBUMINE; INDAPAMIDE

Saadav alates:

PRO DOC LIMITEE

ATC kood:

C09BA04

INN (Rahvusvaheline Nimetus):

PERINDOPRIL AND DIURETICS

Annus:

4MG; 1.25MG

Ravimvorm:

TABLET

Koostis:

PERINDOPRIL ERBUMINE 4MG; INDAPAMIDE 1.25MG

Manustamisviis:

ORAL

Ühikuid pakis:

15G/50G

Retsepti tüüp:

Prescription

Toote kokkuvõte:

Active ingredient group (AIG) number: 0248401001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2021-12-07

Toote omadused

_ _
_PERINDOPRIL ERBUMINE/INDAPAMIDE LD, _
_PERINDOPRIL ERBUMINE/INDAPAMIDE, PERINDOPRIL ERBUMINE/INDAPAMIDE HD _
_(perindopril erbumine / indapamide) Product Monograph _
_Page 1 of 68_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PERINDOPRIL ERBUMINE/INDAPAMIDE LD
Tablets, 2 mg / 0.625 mg Oral
Pr
PERINDOPRIL ERBUMINE/INDAPAMIDE
Tablets, 4 mg / 1.25 mg Oral
Pr
PERINDOPRIL ERBUMINE/INDAPAMIDE HD
Tablets, 8 mg / 2.5 mg Oral
Perindopril Erbumine / Indapamide Tablets
Angiotensin Converting Enzyme Inhibitor / Diuretic
Pro Doc Ltée
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Date of Initial Authorization:
DEC 7, 2021
Date of Revision:
JAN 19, 2023
Submission Control Number: 270493
_ _
_PERINDOPRIL ERBUMINE/INDAPAMIDE LD, _
_PERINDOPRIL ERBUMINE/INDAPAMIDE, PERINDOPRIL ERBUMINE/INDAPAMIDE HD _
_(perindopril erbumine / indapamide) Product Monograph _
_Page 2 of 68_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
01/2023
7 WARNING AND PRECAUTIONS
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics (<18 years of age)
....................................................................................
4
1.2
Geriatrics (> 65 years of age)
...................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................... 5
4
DOSAGE A